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We describe a patient with chronic inflammatory demyelinating polyneuropathy (CIDP) in which an adduction deficit and ptosis in
the left eye presented several years before the polyneuropathy. A 52-year-old man presented with a 14-year history of unremitting
diplopia, adduction deficit, and ptosis in the left eye. At the age of 45 a mild bilateral foot drop and impaired sensation in the
four limbs appeared, with these symptoms showing a progressive course. The diagnostic workup included EMG/ENG which
demonstrated reduced conduction velocity with bilateral and symmetrical sensory and motor involvement. Cerebrospinal fluid
studies revealed a cytoalbuminologic dissociation. A prolonged treatmentwith corticosteroids allowed a significant improvement of
the limbweakness. Diplopia and ptosis remained unchanged.This unusual form of CIDP presented as a long-lasting isolated cranial
nerve palsy. A diagnostic workup for CIDP should therefore be performed in those patients in which an isolated and unremitting
cranial nerve palsy cannot be explained by common causes.
1. Introduction
Chronic inflammatorydemyelinatingpolyneuropathy (CIDP)
is an autoimmune disease that targets the myelin sheath
of peripheral nerves. The clinical picture is heterogeneous
and is often characterized by a progressive or relapsing
motor and/or sensory dysfunction in more than one limb of
peripheral nerve nature [1, 2].
CIDP develops over at least twomonths, and its diagnosis
is mainly based on physiologic and cerebrospinal fluid (CSF)
studies [1]. The response to intravenous immunoglobulins,
corticosteroids, and other immunosuppressants is also a key
feature of CIDP.
The recent EFNS/PNS diagnostic criteria for CIDP have
been validated, showing 81% sensitivity and 96% specificity
[1].
Predominant cranial nerve (CN) involvement is a rela-
tively unusual feature of CIDP [3–5], being described in only
5% of patients in a case series [3]. Oculomotor nerves (III,
IV, and VI) are most often affected, followed by the CN VII
and, more rarely, CN IX, X, and XI. A report showed that
an isolated CN III deficit was a presenting feature of CIDP,
two years before the onset of the symmetric polyneuropathy
[6].
Here, we describe a case with a similar presentation, in
which a nonreversible adduction deficit and ptosis in the left
eye preceded by several years the onset of the polyneuropathy.
2. Case Report
A 52-year-old unmarried man referred to our Neurology
Ward with years-long history of ptosis, adduction deficit in
the left eye, and mild diplopia followed by slowly progressive
sensory deficits, fatigue, and weakness in the lower limbs.
More recently a bilateral foot drop appeared (more pro-
nounced in the right foot) making the walking very difficult.
The onset of ptosis and diplopia was dated back to 14
years whereas the sensory symptoms and weakness appeared
some seven years earlier. For several years the patient did
not seek medical advice. In the past two years he underwent
a brain and spine MRI (both negative) and electromyo-
graphy/nerve conduction studies which showed reduced
Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2015, Article ID 769429, 3 pages
http://dx.doi.org/10.1155/2015/769429
2 Case Reports in Medicine
Figure 1: The left eye adduction deficit and ptosis in the patient. Note the slight ptosis also in the right eye. The left CN III deficit persisted
unmodified after treatment with IVIg and methylprednisolone.
Table 1: Nerve conduction study.
Nerve 𝐴 Decrease (%) CV Decrease (%) DL Increase (%)
R-median (M) 6.0mV 14 40.1m/s 24.1 3.5ms 0.28
R-median (S) 16.0 𝜇V 58 43.3m/s 22.9 3.2ms 12
L-ulnar (M) 5.4mV 5 36.0m/s 32.8 3.9ms 30.1
R-peroneal (M) 2.6mV 55 27.5m/s 38.1 6.1ms 31
L-peroneal (M) 3.0mV 50 38.8m/s 12.6 5.1ms 10.1
R-sural 3.3 𝜇V 80 32.4m/s 28.3 4.3ms 53
𝐴 = amplitude (CMAP or SAP); CV = conduction velocity; DL = distal latency. Data are also expressed as percent decrease or increase with respect to the
normal values reported in [7].
conduction velocity and bilateral and symmetrical sensory
and motor involvement in the four limbs. A diagnosis of
motor-sensory polyneuropathy of unknown cause was made.
The patient is an administrative officer and had never
been exposed to chemicals, pesticides, neurotoxicants, and
heavy metals. He is neither diabetic nor hypertensive. The
family history is negative for hereditary motor-sensory
polyneuropathies (HSMN). The neurological examination
showedmoderate hypotrophy in the four limbs distally, more
prominent in the lower limbs. Walking was difficult because
of a bilateral foot drop. Muscle tone was normal, and tendon
reflexes were diminished in the upper limbs and absent in the
lower limbs. Vibratory sensation was impaired in the lower
limbs.
Visual acuity was 20/20 in both eyes. He had ptosis in the
Oculus Sinister (OS)with a nearly complete adduction deficit.
A slight ptosis without other abnormalities was also evident
in the Oculus Dexter (OD) (Figure 1). Pupils had equal size
in dim illumination and symmetric light reaction.
An extensive biochemical and immunological workup
was performed that did not disclose abnormalities. In partic-
ular, anti-ganglioside antibodies (GM1, GM1b, GQ1b, GD1a,
GD1b, and GT1b) and antimyelin-associated glycoprotein
were negative. CSF analysis showed a cytoalbuminologic
dissociation with one white cell per mm3 and a protein of
82mg/dL. No oligoclonal bands were detected. Electroneu-
romyography demonstrated reduced conduction velocity
with bilateral sensory andmotor involvement (Table 1). Brain
MRI and MR angiography were also performed but did not
show abnormalities. Extensive genetic testing for HSMN I,
including PMP22 duplication and connexin 32 mutations,
gave negative results.
According to the European Federation of Neurological
Societies/Peripheral Nerve Society Guideline on manage-
ment of chronic inflammatory demyelinating polyradicu-
loneuropathy [1], a clinical diagnosis of clinically probable
CIDP was made.
The patient was treated with IVIG (0.5 g/Kg/day for
five days) followed by oral methylprednisolone at a dose
of 8mg/day for several weeks [8]. Muscle strength slightly
improved, but ptosis and the adduction deficit were left
unchanged.
3. Discussion
Cranial nerve involvement is relatively uncommon in CIDP
[3, 5, 9]. Ocular motor involvement is characterized in
most cases by an unilateral and not reversible deficit, often
preceding the limb signs and symptoms by a short interval
[3, 4, 6, 9].
In a case described, a CN III paresis occurred two
years before the onset of the limb weakness and fatigue
[6]. Furthermore, an MRI study demonstrated a bilateral
enhancement of CNV and III, suggesting a more widespread
cranial nerve damage [6].
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Our case adds to this very limited literature, as it shows
a very long interval (i.e., at least seven years) between the
onset of the adduction deficit and ptosis of the OS and
the appearance of the first symptoms of the motor-sensory
polyneuropathy. Interestingly, the clinical inspection revealed
a slight and isolated ptosis also in the right eye, suggesting a
bilateral involvement of CN III. Subclinical or mild cranial
nerve deficits are in fact relatively common in CIDP [1, 3, 4,
6].
Our patient for several years did not pay attention to his
diplopia and left ptosis and sought for a doctor only after the
appearance of the limbs weakness. He did not even notice the
mild ptosis in theOD.Over such a lengthy period of time (i.e.,
fourteen years), the left ophthalmoparesis never showed an
appreciable remission, and our neurophysiological, biochem-
ical, immunological, and imaging studies excluded common
causes of CN III palsies (e.g., diabetes, hypertension, viral
infections, and intracranial aneurysm).Thus, the diagnosis of
CIDP appeared the most plausible, linking the cranial nerves
III deficits and the chronic polyneuropathy.
Anti-ganglioside antibodies, including the IgG anti-GQ1b
gangliosides, which have been found to be associatedwith the
acute ophthalmoplegia in theMiller-Fischer syndrome and in
Guillain-Barre´ syndrome [10], were absent in our case. Lack
of anti-ganglioside antibodies has been already described in
patients with CIDP and ophthalmoplegia [4, 6]. Thus, our
results further support the hypothesis that other antibodies
might be involved in CIDP with ocular motor palsies [6].
In conclusion, we have described a variant of CIDPwhere
a persistent ophthalmoparesis was preceding by years the
appearance of the motor-sensory polyneuropathy. CN III
seems in fact to be particularly susceptible to a permanent
damage due to an autoimmune aggression [4, 6].
Neurophysiological and CSF studies should always be
performed in patients with unremitting ocular motor nerve
palsy not explained by common causes.
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